Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

At the Crossroads: COVID-19 and Immune Checkpoint Blockade for Cancer, Chiara Garassino and Antoni Ribas.

From the Current Issue

  • Research Articles
    Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
    Mara De Martino, Camille Daviaud, Julie M. Diamond, Jeffrey Kraynak, Amandine Alard, Silvia C. Formenti, Lance D. Miller, Sandra Demaria and Claire Vanpouille-Box
    Cancer Immunol Res January 1 2021 9 (1) 89-102; DOI:10.1158/2326-6066.CIR-19-0305

    Activin A and TGFβ can shape the breast cancer tumor microenvironment after radiotherapy. Dual blockade of activin A and TGFβ reverses radiotherapy-induced Treg increases and boosts antitumor responses, highlighting potential targetable factors for breast cancer treatment.

  • Research Articles | AuthorChoice
    The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
    Xiuli Wang, Christian Huynh, Ryan Urak, Lihong Weng, Miriam Walter, Laura Lim, Vibhuti Vyas, Wen-Chung Chang, Brenda Aguilar, Alfonso Brito, Aniee Sarkissian, N. Achini Bandara, Lu Yang, Jinhui Wang, Xiwei Wu, Jianying Zhang, Saul J. Priceman, Hong Qin, Larry W. Kwak, Lihua E. Budde, Sandra H. Thomas, Mary C. Clark, Leslie Popplewell, Tanya Siddiqi, Christine E. Brown and Stephen J. Forman
    Cancer Immunol Res January 1 2021 9 (1) 75-88; DOI:10.1158/2326-6066.CIR-20-0236

    In the clinic, CD19-CAR T cells are administered IV and are not used specifically to treat CNS lymphoma. The authors show a single ICV infusion of CD19-CAR T cells completely eradicates both CNS and systemic lymphoma in mice.

  • Research Articles | AuthorChoice
    A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy
    Si-Qi Liu, Alyssa Grantham, Casey Landry, Brian Granda, Rajiv Chopra, Srinivas Chakravarthy, Sabine Deutsch, Markus Vogel, Katie Russo, Katherine Seiss, William R. Tschantz, Tomas Rejtar, David A. Ruddy, Tiancen Hu, Kimberly Aardalen, Joel P. Wagner, Glenn Dranoff and Joseph A. D'Alessio
    Cancer Immunol Res January 1 2021 9 (1) 34-49; DOI:10.1158/2326-6066.CIR-20-0080

    A genome-wide CRISPR screen was developed to understand cancer cell–derived resistance mechanisms to CD3-bispecific antibodies. The screen identifies IFNγ signaling being pivotal for responsiveness to CD3 bispecifics, and deficiency in core fucosylation as causing resistance to the therapeutic flotetuzumab.

OnlineFirst Articles

Load more

Trending - Altmetric

Advertisement
Back to top